<DOC>
	<DOC>NCT00191048</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of atomoxetine administered once daily in the treatment of children and adolescents with ADHD and comorbid dyslexia.</brief_summary>
	<brief_title>Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Dyslexia</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Patients with ADHD only or ADHD and Dyslexia At least 10 years old and no more than 16 years old IQ score of 80 or more Must be able to swallow capsules Have received treatment within last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry Weigh less than 25 kg or greater than 70 kg Pregnant or breast feeding Documented history of bipolar I or II disorder, or psychosis Documented history of autism, Asperger's syndrome or pervasive developmental disorder</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>